Waldenstrom's disease is a lymphoproliferative disorder that is typically treated with plasmapheresis and/or alkylating agents. In young patients, other lymphoproliferative disorders have been treated with allogeneic transplantation. Two patients with aggressive Waldenstrom's disease, who progressed in spite of multi-agent chemotherapy and autologous stem cell transplantation, in one case, underwent allogeneic transplantation from their HLA-identical donors. Both remain alive with event-free survivals of more than 3, and more than 9 years, respectively. Allogeneic transplantation should be considered for young patients with Waldenstrom's disease.
High-dose chemotherapy with autologous stem cell support is widely used for the treatment of lymphomas and myeloma. 1 In the setting of indolent lymphomas, this therapy is fraught with a high incidence of disease recurrence. 2, 3 Allogeneic bone marrow transplantation (BMT) is being increasingly used to treat young patients with poor prognosis low-grade lymphoproliferative disorders. 4 Waldenstrom's macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with IgM monoclonal paraprotein. This rare lymphoid malignancy usually follows an indolent course. As with other low-grade lymphoid malignancies the disease can have an aggressive course with poor prognostic features that justify innovative or aggressive treatments, including BMT. 5, 6 To our knowledge, however, there have been no previous reports of allogeneic BMT for WM. We report two young patients with aggressive WM who received allogeneic BMTs.
Patients and methods

Case 1
A 34-year-old female was diagnosed in October 1986 with Waldenstrom's macroglobulinemia. The patient presented with autoimmune hemolytic anemia, a monoclonal IgM kappa of 17 g/l, kappa light chains in the urine, involvement of bone marrow, peripheral blood, liver and spleen and generalized lymphadenopathy. Lymph node biopsy showed diffuse small lymphocytic lymphoma with lymphoplasmacytic differentiation. Initial treatment was chlorambucil, steroids and splenectomy. In January 1988 the patient received combination chemotherapy with CHOP (cyclophosphamide, vincristine, adriamycin and prednisone), for a total of six cycles with no response. The monoclonal paraprotein rose to 50 g/l, with diffuse marrow involvement, increased liver and lymph node involvement and B symptoms. The patient had an HLA-identical brother and was referred for BMT. Pre-BMT she had a 60% marrow infiltration by CD5 + , CD19 + , FMC7 + , IgM + , kappa + lymphoid cells, with immunoglobulin heavy chain gene rearrangement by Southern blot. Generalized lymphadenopathy and hepatic nodules were seen on CT scan. The IgM kappa monoclonal paraprotein pre-BMT was 60 g/l, with marked reduction of normal IgG and IgA. The hemoglobin was 105 g/l, platelet count 334 × 10 9 /l, WBC 7.6 × 10 9 /l, with 37% neutrophils and 55% lymphocytes, including 10% lymphoma cells, and the LDH concentration was 749 U/L (normal Ͻ460). Conditioning for BMT consisted of highdose oral chlorambucil (0.6 mg/kg daily for 4 days), cyclophosphamide (60 mg/kg for 2 days, total dose 120 mg/kg) and TBI (fractionated over 4 days, total dose 12.5 Gy). Unmanipulated bone marrow was infused on 4 August 1989. GVHD prophylaxis consisted of CsA plus shortcourse MTX. There were no significant post-transplant complications. Recovery of 0.5 × 10 9 /l neutrophils occurred on day +20 and 50 × 10 9 /l platelets on day +30. There was no acute or chronic GVHD. Donor-recipient chimerism studies were regularly performed after BMT by a PCRbased study of RFLP, with a sensitivity of 5%, and showed complete donor chimerism in both peripheral blood and bone marrow aspirates from 3 months post-BMT onwards.
At that time, CT scans showed no lymphadenopathy or liver nodules. Bone marrow biopsy still showed small paratrabecular lymphoid nodules as described in the nodular PR of CLL. 7 However, no CD5 + , CD19 + , kappa + cells were detected by flow cytometry (sensitivity 0.1-1%). No rearranged immunoglobulin heavy chain genes have been detected in the marrow after transplant. This patient remains event-free with a Karnofsky performance status of 100% on day 3378 post-transplant. A small serum monoclonal IgM kappa band of 2.25 g/l is still detectable by immunofixation, with normal IgG and IgA levels. No light chain proteinuria has been found post-BMT. Table 1 summarizes the patient's follow-up after BMT.
Case 2
A 39-year-old male presented in June 1992 with a history of night sweats, fatigue and pallor. A bone marrow aspirate and biopsy showed a lymphoplasmacytic infiltrate consistent with Waldenstrom's macroglobulinemia. Serum electrophoresis showed an IgM kappa monoclonal protein of 35 g/l. Serum viscosity was 2.1. Urine was negative for Bence-Jones proteins. A CT of the chest, abdomen and pelvis showed pretracheal, retroperitoneal and iliac chain adenopathy (up to 1.5 cm). A bone survey showed no focal lesions. His initial treatment consisted of plasmapharesis and chlorambucil followed 4 months later by three cycles of combination chemotherapy (cyclophosphamide, vincristine and prednisone). The patient received two cycles of 2-CDA for progressive anemia in December 1993. At the time, a CT scan showed cervical, axillary, medistinal and retrocrural adenopathy and a 5.5 × 6 cm mass in the head of the pancreas, but no focal liver lesions. A repeat bone marrow biopsy showed hypercellular marrow with atypical pleomorphic plasmacytoid cells with prominent nucleoli with admixed lymphocytes and plasma cells. Flow cytometry showed an abnormal monoclonal (kappa + ) B cell population comprising 25% of the gate. These B cells were positive for CD19, CD20, CD22 and DR, and negative for CD10, CD34 and CD5. The SIg staining was brightly positive. The IgM kappa monoclonal protein was 17.4 g/l. The patient received two cycles of fludarabine in January 1995 without any response followed by two cycles of MINE (mesna, ifosfamide, mitoxanthrone, etoposide) chemotherapy in June 1995. By then he had hepatomegaly, splenomegaly and bulky adenopathy at the porta hepatis. He received mel- phalan 200 mg/m 2 and a peripheral blood autologous stem cell transplant in July 1995 as salvage prior to allogeneic transplant from his HLA-identical sister. A bone marrow examination following the autologous transplant showed residual Waldenstrom's macroglobulinemia. The uninvolved marrow was hypocellular with a relative increase in immature granulocytes and iron stores. The IgM spike, although lower than previous readings was still present (5.2 g/l). There was also no appreciable change in the persistent adenopathies or soft tissue masses in the abdomen on follow-up CT scans. Repeated packed cell and platelet transfusions were administered due to bleeding episodes and a falling hemoglobin concentration. Before allogeneic BMT, the IgM spike was 5.6 g/l with a normal IgG and markedly reduced IgA. The hemoglobin was 6.3 g/dl, platelet count 18 × 10 3 /l, WBC 3.5 × 10 9 /l, with 76% neutrophils and 19% lymphocytes, and the LDH concentration was 188 U/L (normal Ͻ460).
Conditioning for allogeneic BMT consisted of cyclophosphamide (60 mg/kg for 2 days, total dose 120 mg/kg) and TBI (1350 cGy in nine fractions over 5 days plus 1300 cGy boost to the abdomen in four fractions over 4 days). Unmanipulated marrow was infused on 10 October 1995. GVHD prophylaxis consisted of CsA plus solumedrol. Recovery of neutrophils Ͼ0.5 × 10 9 /l occurred on day +13 and platelets Ͼ20 × 10 9 /l on day +22. The last IgM level, measured a year after the transplant, was 0.45 g/l. Following the transplant, the patient developed chronic extensive GVHD with varying degrees of skin, joint, mouth, lungs and liver GVHD. However, he is currently alive on day 1014 post-BMT with a Karnofsky performance status of 70% and no CT evidence of lymphoma or abnormal protein in the serum.
Conclusions
This report presents two cases of long disease-free survival following allogeneic BMT for Waldenstrom's macroglobulinemia. Both positive outcomes are in line with a recent review of the IBMTR data concerning the use of allogeneic BMT for low grade lymphoid malignancies. 8 One of our patients (No. 2) had undergone an autologous stem cell transplant with persistence of disease. His subsequent allogeneic BMT resulted in complete resolution of the mono-clonal gammopathy and adenopathy. This suggests that, in this patient, graft-versus-lymphoma 9 effect was partly or solely responsible for the apparent cure. Our report supports the use of allogeneic BMT for the treatment Waldenstrom's disease with an aggressive clinical course.
